Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics

Keryx Biopharmaceuticals (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics.

As quoted in the press release:

Separately today, Akebia announced that its stockholders voted to approve the share issuance proposal relating to the merger with Keryx at a special meeting of Akebia stockholders.

“The support of our stockholders for this transaction is gratifying,” said Michael W. Rogers, chairperson of Keryx’s board of directors. “Together, Keryx and Akebia have a promising future as a fully integrated biopharmaceutical company committed to improving the lives of people afflicted with renal diseases and creating value for our stockholders.”

“Over the last five months, the Keryx team has been working hard, planning for the completion of the merger in addition to carrying out their daily responsibilities,” said Jodie P. Morrison, interim chief executive officer and director of Keryx. “I am extremely proud of the entire team and their dedication to working towards a seamless closing and transition. Keryx has an outstanding group of employees and it has been a pleasure to lead the organization during this interim period.”

Click here to read the full press release.